Antibody Radionuclide Conjugates – Precision Treatment in Oncology
Radiopharmaceutical innovation has introduced antibody radionuclide conjugates as a powerful strategy for targeted cancer therapy. These compounds combine biological targeting mechanisms with radioactive components capable of destroying cancer cells.
Researchers are exploring improved antibody designs and radionuclide combinations to increase therapeutic effectiveness. Clinical studies continue to evaluate their potential in treating various forms of cancer.
As targeted therapy advances, antibody radionuclide conjugates may become a key component of personalized oncology treatments.